There is growing public skepticism of the return-on-investment of aid. There is a lack of understanding of how aid money is spent, with the World Health Organisation estimating that around 40% of spending in healthcare is wasted. Foreign aid donations are expected to fall and as such, inefficiencies in aid spending need to be addressed.
Evidence is key:
We can combat such skepticism with a loud and clear commitment by the US and UK administrations to ensure that foreign aid is good value for those giving and for those receiving. Emphasis on analysis, evidence and performance will mean that money spent on aid is money well spent.
A serious and sustained institutionalised effort is needed to analyse and publish every significant aid programme’s return-on-investment.
A potential solution
Our recent publication on F1000Research proposes the establishment of NIDE: a National Institute for Development Effectiveness, to play this role on behalf of the UK.
Modelled along the lines of the National Institute for Health and Care Excellence (NICE), NIDE would be an independent public body accountable to the Government, who would work to reduce low and middle income countries’ (LMICs ) dependence on high-income countries for healthcare aid. NICE produces evidence-based guidance and advice and develops quality standard and performance metrics for the NHS.
NIDE would provide similar services on a global level on behalf of agencies such as: the UK’s Department for International Development (DFID), Global Fund for AIDS, TB and Malaria, UNITAID and Gavi. We suggest that governments should “not invest more than £10m of bilateral aid in any programme that has not been assessed by NIDE”.
Can it be done?
Setting up a NICE-for-aid would hardly be an easy task, but it could build on the work of the International Decision Support Initiative (iDSI) based at Imperial College London funded by the Bill & Melinda Gates Foundation, Rockefeller and DFID. This initiative uses clinical and cost-effective evidence to support low and middle income countries in making better decisions with their healthcare budgets.
In this same way, NIDE should use economic and epidemiological analyses as tools to inform development funders on appropriate co-financing levels, and more importantly what this co-financing should be spent on. The goal is to maximise return-on-investment in the long run, whether this be improved population health, improved workforce productivity, and so on. Helping countries build sustainable capacity to spend their own money in a more effective way, as they transition away from aid, is critical to this endeavour.
Comments